- Report
- May 2025
- 193 Pages
Global
From €3131EUR$3,545USD£2,675GBP
€3479EUR$3,939USD£2,972GBP
- Report
- May 2025
- 150 Pages
Global
From €2384EUR$2,699USD£2,036GBP
- Report
- July 2024
- 150 Pages
Global
From €3930EUR$4,450USD£3,357GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2650EUR$3,000USD£2,263GBP
- Report
- May 2024
- 132 Pages
Global
From €5740EUR$6,499USD£4,903GBP
- Report
- May 2024
- 131 Pages
Global
From €5740EUR$6,499USD£4,903GBP
- Report
- May 2024
- 132 Pages
Global
From €5740EUR$6,499USD£4,903GBP
- Report
- October 2023
- 145 Pages
Global
From €2782EUR$3,150USD£2,376GBP
- Report
- April 2023
- 180 Pages
Global
From €2870EUR$3,250USD£2,452GBP
- Report
- August 2024
- 80 Pages
Japan
From €2628EUR$2,975USD£2,244GBP
€3091EUR$3,500USD£2,640GBP
- Report
- February 2024
- 360 Pages
Global
From €7021EUR$7,950USD£5,998GBP
- Report
- December 2023
- 140 Pages
Global
From €3144EUR$3,560USD£2,686GBP
€3930EUR$4,450USD£3,357GBP
- Report
- November 2020
- 199 Pages
Global
€3974EUR$4,500USD£3,395GBP
- Report
- June 2025
- 50 Pages
Global
From €2340EUR$2,650USD£1,999GBP

Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes.
Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects.
Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more